ABSTRACT
PURPOSE: To present a case of partially reversible retinal toxicity related to a newer epilepsy medication, ezogabine (Potiga). METHODS: Case report with multimodal imaging. PATIENT: A patient presented 9 months after starting ezogabine for a screening eye examination with new retinal pigment abnormalities in the maculas of both eyes. RESULTS: These macular abnormalities are characterized for the first time with multimodal imaging. They were partially reversible after cessation of the drug. CONCLUSION: Ezogabine toxicity presents as pigmentary changes in the macula on fundus examination and has newly described characteristics on imaging that can guide ophthalmologists when they perform the FDA-recommended 6-month screening visits for ocular toxicity.